• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13D/A filed by Charles & Colvard Ltd (Amendment)

    11/20/23 4:15:12 PM ET
    $CTHR
    Consumer Specialties
    Consumer Discretionary
    Get the next $CTHR alert in real time by email
    SC 13D/A 1 tm2331183d1_sc13da.htm SC 13D/A

     

     

    UNITED STATES

      SECURITIES AND EXCHANGE
    COMMISSION

     

    Washington, D.C. 20549

     

    SCHEDULE 13D

    Under the Securities Exchange Act of 1934

    (Amendment No. 1)

     

    CHARLES & COLVARD, LTD.

    (Name of Issuer)

     

    Common Stock

    (Title of Class of Securities)

     

    159765106

    (CUSIP Number)

     

    Clint J. Pete

    Charles & Colvard, Ltd.

    170 Southport Drive 

    Morrisville, NC 27560

    (919) 468-0399

     

    (Name, Address and Telephone Number of Person

    Authorized to Receive Notices and Communications)

     

    November 14, 2023

    (Date of Event which Requires Filing of this Statement)

     

     

    If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of §§240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box. ¨

     

    Note: Schedules filed in paper format shall include a signed original and five copies of the schedule, including all exhibits. See §240.13d-7 for other parties to whom copies are to be sent.

     

    * The remainder of this cover page shall be filled out for a Reporting Person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

     

    The information required on the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

     

     

     

     

    CUSIP No. 159765106
      1.

    Names of Reporting Persons

    Ollin B. Sykes

      2. Check the Appropriate Box if a Member of a Group (See Instructions)
        (a)  ¨
        (b)  ¨
      3. SEC Use Only
      4.

    Source of Funds (See Instructions)

     

    PF and WC (See Item 3)

      5. Check if Disclosure of Legal Proceedings Is Required Pursuant to Items 2(d) or 2(e)     ¨
      6.

    Citizenship or Place of Organization

     

    United States

    Number of
    Shares
    Beneficially
    Owned by
    Each
    Reporting
    Person With
    7. Sole Voting Power
    2,724,499
    (1)  
    8. Shared Voting Power
    135,587
    (2)
    9.

    Sole Dispositive Power

    2,724,499 (1)

    10.

    Shared Dispositive Power

    135,587 (2)

      11.

    Aggregate Amount Beneficially Owned by Each Reporting Person

    2,860,086 (1)(2)

      12. Check if the Aggregate Amount in Row (11) Excludes Certain Shares (See Instructions)   ¨
      13.

    Percent of Class Represented by Amount in Row (11)

     

    9.43% (3)

      14.

    Type of Reporting Person (See Instructions)

     

    IN

               

     

     

    (1) Consists of (i) 736,421 shares held directly by Mr. Sykes; (ii) 188,920 shares held in a SEP IRA controlled by Mr. Sykes; (iii) 95,358 shares held in a Roth IRA controlled by Mr. Sykes; (iv) 153,800 shares held in a traditional IRA controlled by Mr. Sykes; and (v) 1,550,000 shares held by the Sykes & Company PA 401(k) Profit Sharing Plan UA January 1, 1985, of which Mr. Sykes is co-trustee, of which shares 375,000 are held in Mr. Sykes’ personal 401(k) account under such plan.

     

    (2) Consists of 135,587 shares held by Lou S. Sykes, Mr. Sykes’ spouse. Mr. Sykes disclaims beneficial ownership of all of these securities, except to the extent of his pecuniary interest therein.

     

    (3) Based on 30,344,955 shares of common stock issued and outstanding as of November 6, 2023.

     

    2

     

     

    CUSIP No. 159765106
      1.

    Names of Reporting Persons

    Sykes & Company Profit Sharing Plan and Trust

      2. Check the Appropriate Box if a Member of a Group (See Instructions)
        (a)  ¨
        (b)  ¨
      3. SEC Use Only
      4.

    Source of Funds (See Instructions)

     

    WC (See Item 3)

      5. Check if Disclosure of Legal Proceedings Is Required Pursuant to Items 2(d) or 2(e)     ¨
      6.

    Citizenship or Place of Organization

     

    United States

    Number of
    Shares
    Beneficially
    Owned by
    Each
    Reporting
    Person With
    7. Sole Voting Power
    1,550,000
    (4)  
    8. Shared Voting Power
    0
    9.

    Sole Dispositive Power

    1,550,000(4)

    10.

    Shared Dispositive Power

    0

      11.

    Aggregate Amount Beneficially Owned by Each Reporting Person

    1,550,000

      12. Check if the Aggregate Amount in Row (11) Excludes Certain Shares (See Instructions)   ¨
      13.

    Percent of Class Represented by Amount in Row (11)

     

    5.11% (3)

      14.

    Type of Reporting Person (See Instructions)

     

    EP

               

     

     

    (4) Includes 375,000 shares held in Mr. Sykes’ personal 401(k) account under the plan over which Mr. Sykes’ has sole dispositive and voting power.

     

    3

     

     

    CUSIP No. 159765106
      1.

    Names of Reporting Persons

    Lou S. Sykes

      2. Check the Appropriate Box if a Member of a Group (See Instructions)
        (a)  ¨
        (b)  ¨
      3. SEC Use Only
      4.

    Source of Funds (See Instructions)

     

    PF (See Item 3)

      5. Check if Disclosure of Legal Proceedings Is Required Pursuant to Items 2(d) or 2(e)     ¨
      6.

    Citizenship or Place of Organization

     

    United States

    Number of
    Shares
    Beneficially
    Owned by
    Each
    Reporting
    Person With
    7. Sole Voting Power
    0
      
    8. Shared Voting Power
    135,587
    9.

    Sole Dispositive Power

    0

    10.

    Shared Dispositive Power

    135,587

      11.

    Aggregate Amount Beneficially Owned by Each Reporting Person

    135,587

      12. Check if the Aggregate Amount in Row (11) Excludes Certain Shares (See Instructions)   ¨
      13.

    Percent of Class Represented by Amount in Row (11)

     

    0.45% (3)

      14.

    Type of Reporting Person (See Instructions)

     

    IN

               

     

    4

     

     

    Item 1. Security and Issuer
    This Amendment No. 1 to Schedule 13D relates to the shares of common stock, no par value (the “Common Shares”), issued by Charles & Colvard, Ltd., a North Carolina corporation (the “Issuer”). The principal executive offices of the Issuer are located at 170 Southport Drive, Morrisville, North Carolina 27560.
    Item 2. Identity and Background

    (a)  This Statement is being jointly filed by Ollin B. Sykes (“Mr. Sykes”), the Sykes & Company PA 401(k) Profit Sharing Plan UA January 1, 1985 (the “Plan”) and Lou S. Sykes (“Ms. Sykes”). Mr. Sykes, the Plan and Ms. Sykes are referred to collectively as the “Reporting Persons.”

     

    (b) The principal business address of Mr. Sykes is 401 E. Church Street Ext., Floor 3, Edenton, NC 27932. The principal business address of the Plan is 401 E. Church Street Ext., Floor 3, Edenton, NC 27932. The principal address of Ms. Sykes is c/o Ollin B. Sykes, 401 E. Church Street Ext., Floor 3, Edenton, NC 27932.

     

    (c) The principal business occupation of Mr. Sykes is President of Sykes & Company, P.A. Sykes & Company, P.A. is an accounting firm located at 401 E. Church Street Ext., Floor 3, Edenton, NC 27932. The principal business of the Plan is investing in securities.

     

    (d)-(e)  During the last five years, none of the Reporting Persons have been (i) convicted in a criminal proceeding (excluding traffic violations or similar misdemeanors) or (ii) a party to a civil proceeding of a judicial or administrative body of competent jurisdiction and as a result of such proceeding was or is subject to a judgment, decree or final order enjoining future violations of, or prohibiting or mandating activities subject to, federal or state securities laws or finding any violation with respect to such laws.

     

    (f) Mr. Sykes and Ms. Sykes are citizens of the United States of America.

    Item 3. Source and Amount of Funds or Other Consideration

    The 736,421 Common Shares held by Mr. Sykes, the 188,920 Common Shares held in Mr. Sykes’ SEP IRA, the 95,358 Common Shares held in Mr. Sykes’ Roth IRA, and the 153,800 Common Shares held in Mr. Sykes’ traditional IRA, were acquired in gradual increments, from 1997 to present, through (i) a series of purchases made with personal funds and (ii) the exercise of stock options granted to Mr. Sykes in gradual increments by the Issuer in consideration for his services as a director of the Issuer. The stock options to purchase an aggregate of (i) 15,600 Common Shares and (ii) 52,631 Common Shares, which (i) became exercisable on November 17, 2022 and (ii) become exercisable on December 14, 2023, respectively, were granted to Mr. Sykes by the Issuer in consideration for his services as a director of the Issuer.

     

    The 1,550,000 Common Shares held by the Plan were acquired in gradual increments, from 2009 to present, through a series of purchases made with working capital. Of such Common Shares, 375,000 were purchased by the Plan for Mr. Sykes’ personal 401(k) account under the Plan, pursuant to Mr. Sykes’ instructions.

     

    The 135,587 Common Shares held by Ms. Sykes were acquired in gradual increments, from 1997 to present, through a series of purchases made with personal funds.

    Item 4. Purpose of Transaction

    All of the Common Shares beneficially owned by the Reporting Persons were acquired for investment purposes, and in the case of Mr. Sykes, as consideration for his services as a director of the Issuer. As of the date of this statement, the Reporting Person does not have any plans or proposals that would result in any of the matters set forth in subparagraphs (a)-(j) of Item 4 of Schedule 13D except as set forth herein.

     

    Item 5.

    Interest in Securities of the Issuer

     

    (a)

     

    (i) Mr. Sykes beneficially owns 2,860,086 Common Shares, representing approximately 9.43% of issued and outstanding Common Shares.

     

    (ii) The Plan beneficially owns 1,550,000 Common Shares, representing approximately 5.11% of issued and outstanding Common Shares.

     

    (iii) Ms. Sykes beneficially owns 135,587 Common Shares, representing approximately 0.45% of issued and outstanding Common Shares.

     

    The percentages are computed based on 30,344,955 Common Shares issued and outstanding as of November 6, 2023.

     

    (b)

     

    (i) Mr. Sykes has sole voting and dispositive power with respect to 2,724,499 Common Shares, which includes the 736,421 Common Shares held by Mr. Sykes, the 188,920 Common Shares held in Mr. Sykes’ SEP IRA, the 95,358 Common Shares held in Mr. Sykes’ Roth IRA, the 153,800 Common Shares held in Mr. Sykes’ traditional IRA, his options to purchase an aggregate of 15,600 Common Shares (which became exercisable on November 17, 2022) and 44,642 Common Shares (which become exercisable on December 14, 2023), and the 1,550,000 Common Shares held by the Plan of which he is the co-trustee. Mr. Sykes may be deemed to have shared voting and dispositive power with respect to 135,587 Common Shares held by Ms. Sykes, his spouse.

     

    5

     

     

    (ii) The Plan has sole voting and dispositive power with respect to 1,550,000 Common Shares. As trustee of the Plan, Mr. Sykes may be deemed to have voting and dispositive power with respect to such shares. 375,000 of such Common Shares are held in Mr. Sykes’ personal 401(k) account under the Plan.

     

    (iii) Ms. Sykes has shared voting and dispositive power with respect to 135,587 Common Shares. Mr. Sykes, as her spouse, may be deemed to have shared voting and dispositive power with respect to such shares.

     

    (c)

     

    (i) On November 14, 2023, Mr. Sykes purchased an aggregate of 100,000 Common Shares in open market broker transactions at a weighted average price of $0.3181 per Common Share.

     

    (ii) On November 14, 2023, Mrs. Sykes purchased an aggregate of 20,000 Common Shares in open market broker transactions at a price of $0.3374 per Common Share.

     

    (iii) On November 15, 2023, Mrs. Sykes purchased an aggregate of 69,800 Common Shares in open market broker transactions at a weighted average price of $0.3422 per Common Share.

     

    (iv) On November 15, 2023, Mr. Sykes’ traditional IRA purchased an aggregate of 42,300 Common Shares in open market broker transactions at a weighted average price of $0.3583 per Common Share.

     

    (d) Not applicable.

     

    (e) Not applicable.

    Item 6. Contracts, Arrangements, Understandings or Relationships with Respect to Securities of the Issuer
    Mr. Sykes holds stock options to purchase an aggregate of 15,600 Common Shares at an exercise price of $3.205 per Common Share, granted on November 18, 2021. These options were granted by the Issuer in consideration for Mr. Sykes’ services as Director. This option grant vested in full on the date of the Issuer’s 2022 Annual Shareholders’ Meeting, which took place on November 17, 2022, and expire on November 18, 2031. Mr. Sykes also holds stock options to purchase an aggregate of 52,631 Common Shares at an exercise price of $0.95 per Common Share, granted on November 17, 2022. These options were granted by the Issuer in consideration for Mr. Sykes services as Director. This option grant vests in full on the date of the Issuer’s 2023 Annual Shareholders’ Meeting, which is expected to take place on December 14, 2023, and expires on November 17, 2032.
    Item 7. Material to Be Filed as Exhibits
    Exhibit 99.1 - Joint Filing Agreement

     

    6

     

     

    SIGNATURES

     

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     

    November 20, 2023

     

      Ollin B. Sykes
       
      By: /s/ Ollin B. Sykes
        Ollin B. Sykes
       
      Sykes & Company Profit Sharing Plan and Trust
       
      By: /s/ Ollin B. Sykes
      Name: Ollin B. Sykes
      Title: Trustee
       
      Lou S. Sykes
       
      By: /s/ Lou S. Sykes
        Lou S. Sykes

     

    7

     

    Get the next $CTHR alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $CTHR

    DatePrice TargetRatingAnalyst
    9/3/2021$3.50 → $3.75Buy
    Roth Capital
    More analyst ratings

    $CTHR
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • O'Connell Don bought $5,550 worth of shares (15,000 units at $0.37) (SEC Form 4)

      4 - CHARLES & COLVARD LTD (0001015155) (Issuer)

      3/7/24 4:15:57 PM ET
      $CTHR
      Consumer Specialties
      Consumer Discretionary
    • Sykes Ollin B bought $7,028 worth of shares (19,000 units at $0.37) (SEC Form 4)

      4 - CHARLES & COLVARD LTD (0001015155) (Issuer)

      3/5/24 6:21:11 PM ET
      $CTHR
      Consumer Specialties
      Consumer Discretionary
    • O'Connell Don bought $4,806 worth of shares (13,350 units at $0.36), increasing direct ownership by 3% to 464,464 units (SEC Form 4)

      4 - CHARLES & COLVARD LTD (0001015155) (Issuer)

      3/5/24 9:15:15 AM ET
      $CTHR
      Consumer Specialties
      Consumer Discretionary

    $CTHR
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • O'Connell Don bought $5,550 worth of shares (15,000 units at $0.37) (SEC Form 4)

      4 - CHARLES & COLVARD LTD (0001015155) (Issuer)

      3/7/24 4:15:57 PM ET
      $CTHR
      Consumer Specialties
      Consumer Discretionary
    • Sykes Ollin B bought $7,028 worth of shares (19,000 units at $0.37) (SEC Form 4)

      4 - CHARLES & COLVARD LTD (0001015155) (Issuer)

      3/5/24 6:21:11 PM ET
      $CTHR
      Consumer Specialties
      Consumer Discretionary
    • O'Connell Don bought $4,806 worth of shares (13,350 units at $0.36), increasing direct ownership by 3% to 464,464 units (SEC Form 4)

      4 - CHARLES & COLVARD LTD (0001015155) (Issuer)

      3/5/24 9:15:15 AM ET
      $CTHR
      Consumer Specialties
      Consumer Discretionary

    $CTHR
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Charles & Colvard, Ltd. Announces Delisting from Nasdaq

      RESEARCH TRIANGLE PARK, N.C., April 22, 2025 /PRNewswire/ -- Charles & Colvard, Ltd. ("Charles & Colvard" or the "Company"), announced that the Company received a staff determination letter from the Nasdaq Stock Market, LLC ("Nasdaq"), informing the Company that Nasdaq determined to suspend trading and delist the Company's common stock (the "Common Stock") from Nasdaq because the Company is out of compliance with Listing Rule 5250(c)(1) for failure to timely file its Forms 10-Q for the quarters ended September 30 and December 31, 2024, unless the Company appeals this determination. The Company does not intend to request a hearing to appeal this determination. This decision was based on a car

      4/22/25 4:45:00 PM ET
      $CTHR
      Consumer Specialties
      Consumer Discretionary
    • Charles & Colvard, Ltd. Receives Expected Nasdaq Notice Regarding Delayed Form 10-Q

      RESEARCH TRIANGLE PARK, N.C., March 3, 2025 /PRNewswire/ -- Charles & Colvard, Ltd. ("Charles & Colvard" or the "Company") (NASDAQ:CTHR) today announced that on February 25, 2025, it received an expected notice from the Listing Qualifications Department of the Nasdaq Stock Market LLC ("Nasdaq") stating that the Company continues to not be in compliance with Nasdaq Listing Rule 5250(c)(1) (the "Listing Rule"), as a result of not having timely filed its Quarterly Report on Form 10-Q for the fiscal quarter ended December 31, 2024. Nasdaq previously accepted the Company's plan to regain compliance with the Listing Rule and granted the Company until April 14, 2025 to file its Annual Report on For

      3/3/25 4:45:00 PM ET
      $CTHR
      Consumer Specialties
      Consumer Discretionary
    • Charles & Colvard, Ltd. Receives Interim Award in Wolfspeed Arbitration

      RESEARCH TRIANGLE PARK, N.C., Dec. 11, 2024 /PRNewswire/ -- Charles & Colvard, Ltd. ("Charles & Colvard" or the "Company") (NASDAQ:CTHR) today announced that on December 5, 2024, it received an interim award in its confidential arbitration with Wolfspeed, Inc.  Importantly, the award rejected Wolfspeed's claims to expectation damages of approximately $22.8 million, limiting the Company's damages to just $3.3 million representing approximately $1.3 million for inventory previously purchased and approximately $2.0 million of consigned inventory in the Company's possession, that will now be recorded on the Company's balance sheet as of June 30, 2024 - along with interest, arbitration and limite

      12/11/24 4:10:00 PM ET
      $CTHR
      Consumer Specialties
      Consumer Discretionary

    $CTHR
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more

    $CTHR
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more

    $CTHR
    Financials

    Live finance-specific insights

    See more

    $CTHR
    SEC Filings

    See more
    • Roth Capital reiterated coverage on Charles & Colvard with a new price target

      Roth Capital reiterated coverage of Charles & Colvard with a rating of Buy and set a new price target of $3.75 from $3.50 previously

      9/3/21 8:46:46 AM ET
      $CTHR
      Consumer Specialties
      Consumer Discretionary
    • SEC Form SC 13D/A filed by Charles & Colvard Ltd (Amendment)

      SC 13D/A - CHARLES & COLVARD LTD (0001015155) (Subject)

      2/26/24 7:00:57 PM ET
      $CTHR
      Consumer Specialties
      Consumer Discretionary
    • SEC Form SC 13G/A filed by Charles & Colvard Ltd (Amendment)

      SC 13G/A - CHARLES & COLVARD LTD (0001015155) (Subject)

      2/14/24 9:00:30 AM ET
      $CTHR
      Consumer Specialties
      Consumer Discretionary
    • SEC Form SC 13D/A filed by Charles & Colvard Ltd (Amendment)

      SC 13D/A - CHARLES & COLVARD LTD (0001015155) (Subject)

      11/20/23 4:15:12 PM ET
      $CTHR
      Consumer Specialties
      Consumer Discretionary
    • CHARLES & COLVARD REPORTS THIRD QUARTER FISCAL YEAR 2024 FINANCIAL RESULTS

      Conference Call with Accompanying Slide Presentation Scheduled Today at 4:30 PM ET RESEARCH TRIANGLE PARK, N.C., May 2, 2024 /PRNewswire/ -- Charles & Colvard, Ltd. (NASDAQ:CTHR) (the "Company"), a globally recognized fine jewelry company that specializes in moissanite and lab grown diamonds, reported financial results for the third quarter ended March 31, 2024 ("Third Quarter Fiscal 2024").  Management Commentary  "We remain committed to growth despite a challenging third quarter. We believe our strategic initiatives, continued investments in innovative technology, and dedica

      5/2/24 4:07:00 PM ET
      $CTHR
      Consumer Specialties
      Consumer Discretionary
    • CHARLES & COLVARD TO HOST THIRD QUARTER FISCAL YEAR 2024 INVESTOR CONFERENCE CALL ON MAY 2, 2024 AT 4:30 PM ET

      RESEARCH TRIANGLE PARK, N.C., April 23, 2024 /PRNewswire/ -- Charles & Colvard, Ltd. (NASDAQ:CTHR) (the "Company"), a globally recognized fine jewelry company that specializes in moissanite and lab grown diamonds, will host an investor conference call and webcast presentation to discuss its financial results for the third quarter ended March 31, 2024 ("Third Quarter Fiscal Year 2024") at 4:30 p.m. ET on Thursday, May 2, 2024. The Company will release its financial results after market close on the same day. Third Quarter Fiscal Year 2024 Conference Call DetailsDate and Time: T

      4/23/24 4:08:00 PM ET
      $CTHR
      Consumer Specialties
      Consumer Discretionary
    • CHARLES & COLVARD REPORTS SECOND QUARTER FISCAL YEAR 2024 FINANCIAL RESULTS

      Conference Call with Accompanying Slide Presentation Scheduled Today at 4:30 PM ET RESEARCH TRIANGLE PARK, N.C., Feb. 13, 2024 /PRNewswire/ -- Charles & Colvard, Ltd. (NASDAQ:CTHR) (the "Company"), a globally recognized fine jewelry company that specializes in moissanite and lab grown diamonds, reported financial results for the second quarter ended December 31, 2023 ("Second Quarter Fiscal 2024").  Management Commentary  "We acknowledge the recent industry shift has presented us with numerous challenges and has significantly impacted our earnings. However, we do not believe t

      2/13/24 4:07:00 PM ET
      $CTHR
      Consumer Specialties
      Consumer Discretionary
    • SEC Form NT 10-Q filed by Charles & Colvard Ltd

      NT 10-Q - CHARLES & COLVARD LTD (0001015155) (Filer)

      5/16/25 5:06:09 PM ET
      $CTHR
      Consumer Specialties
      Consumer Discretionary
    • Charles & Colvard Ltd filed SEC Form 8-K: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Regulation FD Disclosure, Financial Statements and Exhibits

      8-K - CHARLES & COLVARD LTD (0001015155) (Filer)

      4/22/25 5:02:42 PM ET
      $CTHR
      Consumer Specialties
      Consumer Discretionary
    • SEC Form 10-K filed by Charles & Colvard Ltd

      10-K - CHARLES & COLVARD LTD (0001015155) (Filer)

      4/3/25 4:45:54 PM ET
      $CTHR
      Consumer Specialties
      Consumer Discretionary

    $CTHR
    Leadership Updates

    Live Leadership Updates

    See more
    • Milestone Scientific Announces CEO Transition, with Chairman Neal Goldman Serving as Interim CEO

      ROSELAND, N.J., Nov. 14, 2024 (GLOBE NEWSWIRE) -- Milestone Scientific Inc. (NYSE:MLSS), a leading developer of computerized drug delivery instruments that provide painless and precise injections, today announced that its Chief Executive Officer Arjan Haverhals will retire from his role as an officer of the company on December 31, 2024. Upon his retirement, Mr. Haverhals will continue to serve as a director on the Board and will provide consulting services to ensure continuity and support through the leadership transition. Mr. Haverhals' retirement, following a distinguished career of over 30 years in the medical device and pharmaceutical industries, reflects his desire to spend more ti

      11/14/24 4:00:00 PM ET
      $CTHR
      $MLSS
      Consumer Specialties
      Consumer Discretionary
      Industrial Specialties
      Health Care
    • Charles & Colvard Joins Russell Microcap® Index

      RESEARCH TRIANGLE PARK, N.C., June 28, 2021 /PRNewswire/ -- Charles & Colvard, Ltd. (NASDAQ:CTHR) (the "Company"), a globally recognized fine jewelry company specializing in lab created moissanite and lab grown diamonds, announced today the Company's addition to the Russell Microcap® Index, effective after the US market opens on June 28, 2021, as a part of the Russell indexes annual reconstitution. Membership in the Russell Microcap® Index, which remains in place for one year, means automatic inclusion in the appropriate growth and value style indexes. FTSE Russell determines

      6/28/21 9:16:00 AM ET
      $CTHR
      Consumer Specialties
      Consumer Discretionary